Viking Therapeutics announced it will present two posters at the 33rd European Congress on Obesity highlighting data from its Phase 2 trial of VK2735, an oral and subcutaneous dual GLP-1/GIP receptor agonist for obesity treatment. The Phase 2 VENTURE-Oral trial showed significant weight loss and good tolerability over 13 weeks. Additionally, Viking shared enrollment details of the ongoing Phase 3 VANQUISH-1 trial targeting adults with obesity or overweight with related health issues. These presentations mark important steps in VK2735's clinical development, with further data expected from the Phase 3 study.
An analyst initiates coverage of Sezzle with a strong buy rating and a price target of $169 per share, citing key growth drivers such as subscriber growth, increased purchase frequency, new products like SezzleCash and Sezzle Send, enterprise merchan...
The Official TRUMP token fell over 8% within 24 hours to about $2.27 following $3.39 million USDC withdrawals by team-associated wallets using liquidity positions on Solana. Despite this, the token remains up 61% over the past week, rising from aroun...
Borders & Southern Petroleum is progressing discussions with multiple parties to farm out its Darwin oil discovery in the Falkland Islands, amid growing investor interest driven by accelerated development of the Sea Lion oil project. The company owns...
Solana (SOL) has surged more than 24% in the past week and 43% over the last month, reclaiming the $100 price level. Institutional and whale investors, including DeFi Development Corp (DFDV), which added 19,000 SOL to its 2.3 million token holdings, ...
Dunkin' and BARK opened their first official dog drive-thru in Quincy, Massachusetts, on National Dog Day, offering dog treats, limited-edition bandanas, and plush toys inspired by Dunkin's menu. The event supports the Dunkin' Joy in Childhood Founda...
